GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Asset Turnover

BioDelivery Sciences International (BioDelivery Sciences International) Asset Turnover : 0.15 (As of Dec. 2021)


View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioDelivery Sciences International's Revenue for the three months ended in Dec. 2021 was $43.2 Mil. BioDelivery Sciences International's Total Assets for the quarter that ended in Dec. 2021 was $290.3 Mil. Therefore, BioDelivery Sciences International's Asset Turnover for the quarter that ended in Dec. 2021 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. BioDelivery Sciences International's annualized ROE % for the quarter that ended in Dec. 2021 was 164.56%. It is also linked to ROA % through Du Pont Formula. BioDelivery Sciences International's annualized ROA % for the quarter that ended in Dec. 2021 was 88.02%.


BioDelivery Sciences International Asset Turnover Historical Data

The historical data trend for BioDelivery Sciences International's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Asset Turnover Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.57 0.76 0.74 0.59

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.17 0.17 0.16 0.15

Competitive Comparison of BioDelivery Sciences International's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Asset Turnover falls into.



BioDelivery Sciences International Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BioDelivery Sciences International's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=166.703/( (239.894+324.596)/ 2 )
=166.703/282.245
=0.59

BioDelivery Sciences International's Asset Turnover for the quarter that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2021 )/( (Total Assets (Q: Sep. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=43.154/( (256.07+324.596)/ 2 )
=43.154/290.333
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


BioDelivery Sciences International  (NAS:BDSI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BioDelivery Sciences International's annulized ROE % for the quarter that ended in Dec. 2021 is

ROE %**(Q: Dec. 2021 )
=Net Income/Total Stockholders Equity
=255.56/155.2985
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(255.56 / 172.616)*(172.616 / 290.333)*(290.333/ 155.2985)
=Net Margin %*Asset Turnover*Equity Multiplier
=148.05 %*0.5945*1.8695
=ROA %*Equity Multiplier
=88.02 %*1.8695
=164.56 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BioDelivery Sciences International's annulized ROA % for the quarter that ended in Dec. 2021 is

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=255.56/290.333
=(Net Income / Revenue)*(Revenue / Total Assets)
=(255.56 / 172.616)*(172.616 / 290.333)
=Net Margin %*Asset Turnover
=148.05 %*0.5945
=88.02 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


BioDelivery Sciences International Asset Turnover Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.
Executives
James Vollins officer: See Remarks C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd director C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho officer: See Remarks 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey director, officer: Chief Executive Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc director 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha officer: See Remarks 1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr director BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier director, officer: Chief Executive Officer C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith officer: Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612

BioDelivery Sciences International (BioDelivery Sciences International) Headlines

From GuruFocus

3 Magic Formula Health Care Stock Picks

By Alberto Abaterusso Alberto Abaterusso 04-19-2021